This company listing is no longer active
5RT Stock Overview
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rubius Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.013 |
| 52 Week High | US$1.40 |
| 52 Week Low | US$0.013 |
| Beta | 2.39 |
| 11 Month Change | 0% |
| 3 Month Change | -23.53% |
| 1 Year Change | n/a |
| 33 Year Change | -99.75% |
| 5 Year Change | n/a |
| Change since IPO | -99.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5RT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | n/a | -17.2% | 8.2% |
Return vs Industry: Insufficient data to determine how 5RT performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 5RT performed against the German Market.
Price Volatility
| 5RT volatility | |
|---|---|
| 5RT Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5RT's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 5RT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 6 | Craig Jalbert | www.rubiustx.com |
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.
Rubius Therapeutics, Inc. Fundamentals Summary
| 5RT fundamental statistics | |
|---|---|
| Market cap | €1.73m |
| Earnings (TTM) | -€167.23m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs 5RT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5RT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$179.67m |
| Earnings | -US$179.67m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.99 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 5RT perform over the long term?
See historical performance and comparison